Bank of New York Mellon
ANTX icon

Bank of New York Mellon’s AN2 Therapeutics ANTX Stock Holding History

Bank of New York Mellon’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Buy
+67,676
New +$291K ﹤0.01% 3957
2023
Q2 		– Sell
-31,684
Closed -$313K – 4387
2023
Q1 		$313K Buy
31,684
+824
+3% +$9.16K ﹤0.01% 3723
2022
Q4 		$294K Buy
30,860
+17,279
+127% +$231K ﹤0.01% 3802
2022
Q3 		$236K Buy
+13,581
New +$158K ﹤0.01% 3949

Other funds holding ANTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of New York Mellon's ANTX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 67,676 shares worth $328K. The stake represents ﹤0.01% of the portfolio and ranks #3957 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in ANTX as recently as Q1 2023.

Bank of New York Mellon first reported a position in ANTX in Q3 2022 and has held it in 4 quarters since. 22 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Bank of New York Mellon held 67,676 shares of AN2 Therapeutics worth $328K as of Q2 2026.
  • AN2 Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3957 holding.
  • Bank of New York Mellon first reported a position in AN2 Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 22 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.